BOTHELL, Wash.--(BUSINESS WIRE)--FUJIFILM SonoSite, Inc., the world leader and specialist in bedside and point-of-care ultrasound, recognizes Life Line Screening for providing access to preventive screening services and encouraging millions of people to take a proactive approach to their health. With point-of-care ultrasound visualization, Life Line Screening’s clinicians are able to look inside a patient’s body to identify disease that could otherwise remain asymptomatic and undetected. As a leading provider of community-based preventive health screening events for almost 20 years, Life Line Screening has administered over seven million screenings.
“Life Line Screening provides valuable, even life-altering, services to patients around the globe and we are excited to partner with the leader in community-based preventive screenings”
Colin Scully, Life Line Screening’s Chairman and CEO, said, “Life Line Screening is committed to ensuring the highest level of accuracy in our screenings and ultrasound visualization is an important tool that plays a vital role in providing non-invasive screening tests to our customers. In collaborating with SonoSite, we have access to the highest quality of point-of-care ultrasound systems. Given SonoSite’s history of reliability and robustness, we are confident their products will continue to provide utmost accuracy to our customers.”
“Life Line Screening provides valuable, even life-altering, services to patients around the globe and we are excited to partner with the leader in community-based preventive screenings,” said Kevin M. Goodwin, SonoSite’s President and CEO. “We are proud that our technology will continue to aid in facilitating screenings for potentially life-saving conditions and be a part of Life Line Screening’s mission to make screenings more accessible and widespread.”
Quinton Goodwin, a customer of Life Line Screening (no relation to Kevin Goodwin), had a life-changing outcome after attending a Life Line Screening event. Despite a family history of abdominal aortic aneurysms, Quinton was not undergoing regular monitoring of his abdominal aorta. “I’m a person that diligently visits my doctor for annual check-ups and found it unnecessary to go through extra health screenings,” Mr. Goodwin declared. Taking control of the situation and her husband’s health, Quinton’s wife encouraged him to attend a local screening event where he discovered a five centimeter abdominal aortic aneurysm that needed immediate medical attention, “Now, I’m very thankful that I was encouraged by my wife to get screened. I went to the screening event feeling great, so when I received my test results, they nearly knocked me over. Undergoing this preventive health screening has given me my life and I’m now a true believer in their existence.” Click here to watch Quinton Goodwin’s story.
In addition to providing non-invasive ultrasound screening tests for risks of stroke and cardiovascular disease, Life Line Screening also offers other screenings for osteoporosis risk and additional laboratory testing for cholesterol, diabetes, kidney disease, and others. All examinations are performed by highly trained healthcare professionals using advanced technology.
About Life Line Screening
Life Line Screening is the nation’s leading provider of community-based preventive health screenings and is a CLIA-certified moderately complex lab. For more information, visit http://www.lifelinescreening.com or http://www.lifelinescreeningblog.com or call 1-800-697-9721.
About FUJIFILM SonoSite, Inc.
FUJIFILM SonoSite, Inc., is the innovator and world leader in bedside and point-of-care ultrasound and an industry leader in ultra high-frequency micro-ultrasound technology. Headquartered near Seattle, the company is represented by 26 subsidiaries and a global distribution network in over 100 countries. SonoSite’s portable, compact systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high-performance ultrasound to the point of patient care. For more information, go to: www.sonosite.com.